Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2022-01-07 00:00:00 ET · period of report 2022-01-05 · accession 0001209191-22-002416 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-07 | 2022-01-05 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| D | 2022-01-07 | 2022-01-05 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $60.00 | -2,650 | 85.7K | -3% | -$159.0K |
| D | 2022-01-07 | 2022-01-05 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.00 | -2,650 | 92.6K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-05 | M | A | 2,650 | $0.3 | 88,350 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-05 | S | D | 2,650 | $60.00 | 85,700 | D | — | — | |
| 3 | Derivative | Employee Stock Option (right to buy) | 2022-01-05 | M | D | 2,650 | $0.00 | 92,605 | D | $0.3 · — to 2028-03-25 | 2,650 Common Stock | (F2) Immediately exercisable. |